文献速递MDS 与骨髓增殖性肿瘤

缺氧诱导因子1是JAK2V617F阳性骨髓增殖性肿瘤的新治疗靶点

Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms.
PubMed 文献 · Leukemia · 2019-11-14

该研究探讨了药理学抑制和shRNA介导的HIF-1α敲低对JAK2V617F阳性细胞的影响。研究发现,echinomycin抑制HIF-1与HRE结合可选择性损害JAK2V617F阳性细胞的生长与存活,诱导凋亡和细胞周期阻滞,并减少集落形成,而健康供者细胞不受影响。机制可能涉及HIF-1靶基因调控的Warburg效应。

要点

  • HIF-1抑制选择性损害JAK2V617F阳性细胞的生长和存活。
  • Echinomycin抑制HIF-1与HRE结合,诱导凋亡和细胞周期阻滞。
  • 机制可能涉及HIF-1靶基因介导的Warburg效应。

核心结论

  • HIF-1是JAK2V617F阳性骨髓增殖性肿瘤的新潜在治疗靶点。

研究设计与样本

  • 研究采用药理学抑制和shRNA介导的HIF-1α敲低,在JAK2V617F阳性细胞系、患者骨髓和外周血单核细胞及iPS细胞来源祖细胞中进行体外实验。

主要发现

  • Echinomycin抑制HIF-1与HRE结合,经ChIP验证,在Jak2V617F阳性32D细胞中诱导凋亡和细胞周期阻滞,损害生长和存活,而Jak2WT对照不受影响。
  • Echinomycin选择性消除JAK2V617F细胞的克隆生长,并降低JAK2V617F阳性患者骨髓和外周血单核细胞及iPS细胞来源祖细胞的生长、存活和集落形成,健康供者细胞不受影响。
  • HIF-1靶基因涉及Warburg效应,如Pdk1、Glut1等表达增加,原代患者样本转录组分析支持这一机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are a heterogeneous group of hematopoietic malignancies including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The JAK2V617F mutation plays a central role in these disorders and can be found in 90% of PV and ~50-60% of ET and PMF. Hypoxia-inducible factor 1 (HIF-1) is a master transcriptional regulator of the response to decreased oxygen levels. We demonstrate the impact of pharmacological inhibition and shRNA-mediated knockdown (KD) of HIF-1α in JAK2V617F-positive cells. Inhibition of HIF-1 binding to hypoxia response elements (HREs) with echinomycin, verified by ChIP, impaired growth and survival by inducing apoptosis and cell cycle arrest in Jak2V617F-positive 32D cells, but not Jak2WT controls. Echinomycin selectively abrogated clonogenic growth of JAK2V617F cells and decreased growth, survival, and colony formation of bone marrow and peripheral blood mononuclear cells and iPS cell-derived progenitor cells from JAK2V617F-positive patients, while cells from healthy donors were unaffected. We identified HIF-1 target genes involved in the Warburg effect as a possible underlying mechanism, with increased expression of Pdk1, Glut1, and others. That was underlined by transcriptome analysis of primary patient samples. Collectively, our data show that HIF-1 is a new potential therapeutic target in JAK2V617F-positive MPN.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Baumeister J, Chatain N, Hubrich A, et al. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. Leukemia. 2019. PMID: 31728053. doi:10.1038/s41375-019-0629-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。